EyePoint reports Q2 EPS (85c), consensus (80c)

Reports revenue $5.3M, consensus $6.16M. “In recent months, we continued our track record of exceptional execution across all aspects of the business, most notably completing enrollment in both pivotal Phase 3 trials, LUGANO and LUCIA, in wet AMD in record time for this indication,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint (EYPT). “The noteworthy physician and patient enthusiasm we have seen for our Phase 3 program across U.S. and international sites-supported by DURAVYU’s robust Phase 2 efficacy and safety data package and our patient-centric, well-understood trial design-has reinforced the clear need and global demand for more durable wet AMD therapies and the role that DURAVYU can play in meaningfully extending the wet AMD treatment paradigm. With topline LUGANO data anticipated in mid-2026, LUCIA data to closely follow, and registration batches underway at our state-of-the-art, commercial manufacturing facility in Northbridge, Massachusetts, we believe we are well-positioned for DURAVYU to be first-to-market among investigational sustained release treatments for wet AMD. We look forward to providing an update on our DURAVYU pivotal plan in DME in the coming months as we work to deliver innovative therapeutics for multiple serious retinal diseases.”